# A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer

Source: https://onco.cc/trials/nct07692204/  
OnCo record `nct07692204` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SAR445877 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Sanofi, now recruiting.

## Summary

A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer is a phase 2 interventional study registered as NCT07692204 by Sanofi, with 30 participants planned, started 2026-07-01 and due to reach its primary completion in 2028-08-02. Interventions recorded: SAR445877.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07692204
- Phase: 2
- Setting: A Phase 2, Open-label, Dose Optimization/Expansion Study of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Gastric or Gastroesophageal Junction Cancer
- Sponsor: Sanofi
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07692204: https://clinicaltrials.gov/study/NCT07692204

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct07692204.json